Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids (IBERICA)
Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression
Sponsor: Eurotrials Brasil Consultores Cientificos Ltda
Terminated
Recruitment became very slow.
Listed as NCT01324934, this PHASE3 trial focuses on Renal Transplant Rejection and remains terminated or withdrawn. Sponsored by Eurotrials Brasil Consultores Cientificos Ltda, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eurotrials Brasil Consultores Cientificos Ltda
- Neovii Biotech
- PsyConsult
- Recerca Clínica S.L.
For direct contact, visit the study record on ClinicalTrials.gov .